BioDlink Biopharm Co Ltd, a China-based global contract development and manufacturing organisation (CDMO), announced on Friday that it recently hosted its 2025 Peer Advisory Board, spotlighting China's clinical trial and CDMO landscape as a global springboard for biotech innovation.

At this event, themed 'Advancing Innovative Drugs Together Worldwide', BioDlink, alongside partners BioPlus, Cobetter, NanoMicro Technology, and Hengyu Biotech, convened top biotech CEOs, MNC executives, research leaders and investment management to discuss how innovative biotech companies could leverage China's rapidly evolving clinical trial and CDMO ecosystem.

Backed by 15 years of operational experience, BioDlink says that it combines advanced biologics development and manufacturing capabilities with a synergistic industrial ecosystem. It also enables biotech companies to fast-track clinical programmes, optimise development budgets, and undertake global regulatory filings while complying with global quality standards.

This event also marked the official launch of BioDlink's English-language brand, with 'Bio' representing biopharma excellence in large molecules; 'D' representing drug-driven and innovation-focused, specialising in ADC/XDC development and manufacturing, and honouring its legacy with a capitalised first letter of 'Dongyao'; and 'link' representing precise bioconjugation and linker technology to connect the world to a BioDlink-centric ecosystem.